Apertor Pharmaceuticals Inc. was founded in November 2020. Our goal is to bring new therapies to patients by disrupting diease-causing protein complexes via proximity induction with heterobifunctional drugs. Our recipe for innovation combines a world-class synthetic biology platform using non-model organisms; a deep knowledge of complex natural products relevant to human health; a computational pipeline enabled by structure-guided design. The result is a first-in-class approach to solving important pharmacological problems and delivering new, high-value treatment options for patients.

Check out our Company Website at: https://apertorpharma.com/